AstraZeneca’s dual Bcl-2/Bcl-xL inhibitor, AZD4320, was intended as an intravenously administered drug with an intermittent dosing schedule, with the aim of achieving rapid Bcl-2/Bcl-xL inhibition in tumour cells whilst enabling recovery from on-target thrombocytopenia between dosing8. This evidence concerns the gene BCL2L1 and neoplasm.